We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Signs Consent Decree to Resolve Paxil cGMP Problems
GSK Signs Consent Decree to Resolve Paxil cGMP Problems
May 2, 2005
GlaxoSmithKline (GSK) expects to begin resupplying the U.S. and foreign markets with Paxil CR and Avandamet by midyear after reaching a consent decree agreement with the FDA regarding manufacturing violations at its Cidra, Puerto Rico, plant.